ArticleNutrients2019
Biological Evaluation and Docking Analysis of Potent BACE1 Inhibitors from
Article in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Rhizomes as Multi-Target Pharmacological Platforms Against Tauopathy: Neuro-Metabolic Crosstalk, Drug-Likeness, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Pinostrobin attenuates microglia-mediated neuroinflammation after subarachnoid hemorrhage through modulation of the MYC-CTSL signaling axis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Flavonoid and Chalcone Scaffolds as Inhibitors of BACE1: Recent Updates.Combinatorial chemistry & high throughput screening · 2024Review
- Discovery of Pinostrobin as a Melanogenic Agent in cAMP/PKA and p38 MAPK Signaling Pathway.Nutrients · 2022Article
- Protective Effects of Flavonoids against Alzheimer's Disease: Pathological Hypothesis, Potential Targets, and Structure-Activity Relationship.International journal of molecular sciences · 2022Review
- Molecular Targets of Pinocembrin Underlying Its Regenerative Activities in Human Keratinocytes.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Structure-Activity Relationship Analysis of Flavonoids and Its Inhibitory Activity Against BACE1 Enzyme Toward a Better Therapy for Alzheimer's Disease.Frontiers in chemistry · 2022Article
- Anticancer Activity of Natural and Synthetic Chalcones.International journal of molecular sciences · 2021Review
- Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.Bioorganic chemistry · 2021Review
- Therapeutic Potential of Phytoconstituents in Management of Alzheimer's Disease.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Discovery of Sulforaphane as a Potent BACE1 Inhibitor Based on Kinetics and Computational Studies.Nutrients · 2020Article
- Article
- Baicalein as a Potential Inhibitor against BACE1 and AChE: Mechanistic Comprehension through In Vitro and Computational Approaches.Nutrients · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is an irreversible neurodegenerative disorder characterized by progressive impairment of cognitive functions. Beta-site amyloid precursor protein cleaving enzyme1 (BACE1) is essential for the formation of β-amyloid peptide (Aβ), a major constituent of amyloid plaques that represent a neuropathological hallmark of this disorder. To find alternative therapies for AD sourced from natural products, the present study focused on three flavonoids from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.